Christopher Richard Anzalone Sells 130,000 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 130,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $68.85, for a total value of $8,950,500.00. Following the completion of the transaction, the chief executive officer owned 3,971,255 shares of the company’s stock, valued at approximately $273,420,906.75. The trade was a 3.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

• On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $62.58, for a total transaction of $3,397,968.84.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $64.80 on Thursday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $72.36. The firm has a 50 day moving average of $47.22 and a two-hundred day moving average of $30.50. The firm has a market capitalization of $8.81 billion, a PE ratio of -809.90 and a beta of 1.28.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright boosted their price target on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Chardan Capital restated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Royal Bank Of Canada lifted their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Finally, Piper Sandler boosted their target price on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $61.89.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ARWR. Marex Group plc acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $576,000. Marshall Wace LLP grew its stake in Arrowhead Pharmaceuticals by 3,507.8% during the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares in the last quarter. Moody Lynn & Lieberson LLC acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at about $213,000. Norges Bank purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $30,414,000. Finally, CWM LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 159.4% during the 2nd quarter. CWM LLC now owns 11,415 shares of the biotechnology company’s stock worth $180,000 after purchasing an additional 7,014 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.